Breaking News Instant updates and real-time market news.

RPD

Rapid7

$33.37

0.38 (1.15%)

, AKAM

Akamai

$80.93

0.36 (0.45%)

04:55
06/14/18
06/14
04:55
06/14/18
04:55

Stephens to hold a bus tour

Boston Software Bus Tour travels throughout Boston on June 13-14.

RPD

Rapid7

$33.37

0.38 (1.15%)

AKAM

Akamai

$80.93

0.36 (0.45%)

CYBR

CyberArk

$65.66

0.11 (0.17%)

LOGM

LogMeln

$106.95

-1.2 (-1.11%)

  • 14

    Jun

  • 14

    Jun

  • 21

    Jun

  • 26

    Jun

RPD Rapid7
$33.37

0.38 (1.15%)

02/28/18
STFL
02/28/18
INITIATION
Target $32
STFL
Buy
Rapid7 initiated with a Buy at Stifel
Stifel analyst Gur Talpaz started Rapid7 with a Buy rating and $32 price target. The analyst believes the company can sustain 30%-plus annualized recurring revenue growth through 2020. Talpaz views Rapid7 as one of the "key players within the fast growing" vulnerability assessment marketplace.
05/09/18
KEYB
05/09/18
NO CHANGE
Target $35
KEYB
Overweight
Rapid7 price target raised to $35 from $30 at KeyBanc
KeyBanc analyst Rob Owens raised his price target for Rapid7 to $35 from $30, citing "strong" Q1 results, supported by accelerating ARR growth to 38% and raised revenue guidance. The analyst reiterates an Overweight rating on the shares.
04/10/18
DADA
04/10/18
INITIATION
DADA
Neutral
Rapid7 initiated with a Neutral at DA Davidson
DA Davidson analyst Mark Kelleher initiated Rapid7 with a Neutral rating and a $28 price target, saying that while he views the company as well positioned for long-term growth, he believes that growth is already reflected in the current stock price.
04/13/18
BTIG
04/13/18
INITIATION
Target $34
BTIG
Buy
Rapid7 initiated with a Buy at BTIG
BTIG analyst Joel Fishbein initiated Rapid7 with a Buy and $34 price target telling investors it has successfully evolved to an end to end provider of security and IT analytics and automation solutions fro SecOps from a niche vulnerability management vendor. Fishbein said the transition to a subscription model provides investors with visibility into profitability next year, reducing a major overhang.
AKAM Akamai
$80.93

0.36 (0.45%)

05/01/18
CHLM
05/01/18
NO CHANGE
Target $91
CHLM
Buy
Akamai price target raised to $91 from $84 at Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee raised his price target for Akamai to $91 from $84 saying the company "crushed" the quarter on the top and bottom line and guided well ahead. The analyst reiterates a Buy rating on the shares.
05/01/18
FBNS
05/01/18
NO CHANGE
Target $80
FBNS
Outperform
Akamai price target raised to $80 from $70 at FBN Securities
FBN Securities analyst Shebly Seyrafi raised his price target on Akamai to $80 after the company's continued strong Cloud Security growth and accelerating CDN and other revenue growth lead to revenue and EPS beating expectations in Q1. Higher media traffic volumes than the company expected were driven by robust traffic from video delivery and gaming customers as well as strong traffic from several sports events, he noted. Seyrafi maintains an Outperform rating on Akamai.
05/16/18
DADA
05/16/18
DOWNGRADE
Target $181
DADA
Neutral
F5 Networks downgraded to Neutral at DA Davidson on valuation
As noted earlier, DA Davidson analyst Mark Kelleher downgraded F5 Networks to Neutral from Buy and kept his $181 price target. The analyst says the positive factors working in the company's favor, such as its ongoing new iSeries product cycle, high gross margins, strong cash flows, and the application of it security solutions have become increasingly more evident after its last earnings report and have since been reflected in the valuation on the stock. Kelleher adds that F5's competitors in security - Akamai (AKAM), Imperva (IMPV), and Radware (RDWR) - also posted strong results, and it may be difficult to expand operating margins amid "high level of competition on the security side of the business".
05/01/18
OPCO
05/01/18
NO CHANGE
Target $90
OPCO
Outperform
Akamai price target raised to $90 from $80 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for Akamai to $90 from $80, citing "strong" quarter and guidance. The analyst reiterates an Outperform rating on the shares.
CYBR CyberArk
$65.66

0.11 (0.17%)

05/04/18
JPMS
05/04/18
NO CHANGE
Target $60
JPMS
Neutral
CyberArk price target raised to $60 from $50 at JPMorgan
JPMorgan analyst Sterling Auty raised his price target for CyberArk to $60 saying the company posted one of "cleanest quarters so far this earnings season in cyber security." CyberArk reported "solid" sales results with license revenue coming in ahead of expectations and let all of the upside drop through to the bottom line creating a significant beat for earnings, Auty tells investors in a post-earnings research note. The analyst notes, however, that the March quarter outlook indicates the company needs a higher level of investment to drive growth. Auty keeps a Neutral rating on CyberArk.
06/07/18
UBSW
06/07/18
NO CHANGE
Target $71
UBSW
Buy
CyberArk price target raised to $71 from $64 at UBS
UBS analyst Fatima Boolani raised her price target on CyberArk to $71 from $64 after meeting with management. The analyst cited better visibility into growth drivers, a sales organization on much more stable footing than a year ago, an easier to consume portfolio, and technical advancements that have removed adoption friction. Boolani reiterated her Buy rating on CyberArk shares.
03/09/18
BOFA
03/09/18
UPGRADE
Target $60
BOFA
Buy
CyberArk upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Daniel Bartus upgraded CyberArk to Buy from Neutral and increased its price target to $60 from $51. Bartus said CyberArk is one of the strongest companies in the high growth market of Privileged Account Management, one of the most critical areas of security, has an attractive relative valuation, and recurring revenue streams that are under-appreciated. The analyst is positive on market tailwinds and sees the potential for 20%+ CAGR through 2020.
03/07/18
PIPR
03/07/18
NO CHANGE
Target $59
PIPR
Overweight
CyberArk price target raised to $59 from $53 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski raised his price target for CyberArk Software to $59 and reiterates an Overweight rating on the shares after attending the company's analyst day. The analyst believes CyberArk is well positioned in the privileged access management market and sees large cross-selling opportunities. He modestly raised his estimates for fiscal 2019.
LOGM LogMeln
$106.95

-1.2 (-1.11%)

05/24/18
PIPR
05/24/18
NO CHANGE
Target $140
PIPR
Overweight
LogMeln shares have 'significant upside,' says Piper Jaffray
After hosting investor meetings with management, Piper Jaffray analyst Alex Zukin says shares of LogMeln have "significant upside" from current levels. The company's product and go-to-market changes aimed at directly combating a changing competitive landscape are set to benefit bookings in the second half of 2018, Zukin tells investors in a research note. He views the current valuation as "compelling" and believes upside will be drive by "consistent beat and raise execution, potential for accelerating revenue growth, and a multiple re-rating in line with our peer group." The analyst keeps an Overweight rating on LogMeln with a $140 price target.
04/06/18
KEYB
04/06/18
INITIATION
Target $135
KEYB
Overweight
LogMeln initiated with an Overweight at KeyBanc
KeyBanc analyst Alex Kurtz started LogMeln with an Overweight rating and $135 price target. The analyst believes the current valuation provides an attractive entry point. Investors should own the shares ahead of gains in sales force productivity and monetization of cross-selling opportunities, Kurtz tells investors in a research note. He believes cross-selling opportunities among LogMeln's 2.3M customer base is still early and that the current free cash flow yield is attractive.
04/27/18
JPMS
04/27/18
NO CHANGE
Target $145
JPMS
Overweight
JPMorgan 'very surprised' by post-earnings selloff in LogMeln
LogMeln reported "very impressive" Q1 results with pro forma revenue growth of 8.2% and earnings per share upside of 4c, JPMorgan analyst Sterling Auty tells investors in a research note. He's "very surprised" by the corresponding stock selloff. Investors took issue with the company lowering the EBITDA forecast by $5M for the acquisition of Jive Communications, Auty contends. He believes the acquisition brings a 20% growing asset in the UCaaS space into a collaboration business that has been growing 5%. This should give LogMeln a "complete solution" that will be "highly competitive in the market for years to come," the analyst writes. Auty keeps an Overweight rating on LogMeln with a $145 price target. The stock in premarket trading is down 8% to $119.60.
04/27/18
BARD
04/27/18
NO CHANGE
Target $145
BARD
Outperform
LogMeln weakness a buying opportunity, says Baird
Baird analyst William Power noted LogMeIn sold off following Q1 results as its guidance commentary included a cut to EBITDA due to higher depreciation and interest expense. The analyst said the stand-alone business appears to be performing well and the free cash flow outlook remains strong. Power said he would use the weakness in LogMeIn as a buying opportunity and reiterated his Outperform rating and $145 price target on the shares.

TODAY'S FREE FLY STORIES

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23
Hot Stocks
Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes »

Amgen announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18
Hot Stocks
Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes »

Two investigational doses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14
Hot Stocks
Ironwood announced Praliciguat phase IIa study data »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

12:07
06/23/18
06/23
12:07
06/23/18
12:07
Hot Stocks
Array BioPharma announces updated results from Phase 3 BEACON CRC trial »

Array BioPharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

DDAIF

Daimler AG

$0.00

(0.00%)

, BMWYY

BMW

$0.00

(0.00%)

11:42
06/23/18
06/23
11:42
06/23/18
11:42
Periodicals
EU to respond to any U.S. auto tariffs, Reuters reports »

The EU will respond to…

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$67.60

-0.2 (-0.29%)

, GE

General Electric

$13.05

0.29 (2.27%)

11:27
06/23/18
06/23
11:27
06/23/18
11:27
Periodicals
Adding Walgreens to Dow may be wrong move, Barron's says »

The guardians of Dow…

WBA

Walgreens Boots Alliance

$67.60

-0.2 (-0.29%)

GE

General Electric

$13.05

0.29 (2.27%)

FB

Facebook

$201.39

-0.07 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

, C

Citi

$67.20

-0.43 (-0.64%)

11:04
06/23/18
06/23
11:04
06/23/18
11:04
Periodicals
Banks to get green light to increase dividends, share repurchases, Barron's says »

Big banks are expected to…

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

C

Citi

$67.20

-0.43 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 26

    Jul

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

MD

Mednax

$44.99

-0.11 (-0.24%)

10:59
06/23/18
06/23
10:59
06/23/18
10:59
Periodicals
Mednax shares may be at risk amid hospital fights, Barron's says »

After peaking in 2015,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

10:25
06/23/18
06/23
10:25
06/23/18
10:25
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

TWTR

Twitter

$45.90

0.68 (1.50%)

, FOXA

21st Century Fox

$48.59

0.25 (0.52%)

10:21
06/23/18
06/23
10:21
06/23/18
10:21
Periodicals
Biggest winner of World Cup could be Twitter, Barron's says »

Twitter's (TWTR)…

TWTR

Twitter

$45.90

0.68 (1.50%)

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

FB

Facebook

$201.39

-0.07 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AAPL

Apple

$184.85

-0.63 (-0.34%)

, DDAIF

Daimler AG

$0.00

(0.00%)

10:10
06/23/18
06/23
10:10
06/23/18
10:10
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$184.85

-0.63 (-0.34%)

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

STMP

Stamps.com

$252.60

0.65 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$74.81

-0.11 (-0.15%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
IntercontinentalExchange management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

AMGN

Amgen

$184.86

-1.14 (-0.61%)

, ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO World Congress on…

AMGN

Amgen

$184.86

-1.14 (-0.61%)

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.07

-0.52 (-2.80%)

INCY

Incyte

$74.02

1.55 (2.14%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

MRK

Merck

$61.46

0.295 (0.48%)

SHPG

Shire

$161.73

-0.7 (-0.43%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.98

0.96 (2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.